Abstract
It was 11 March 2020 when the World Health Organization (WHO) declared the name COVID-19 for coronavirus disease and also described it as a pandemic. Till that day 118,000 cases were confirmed of pneumonia with breathing problem throughout the world. At the start of New Year when COVID-19 came into knowledge a few days later, the gene sequencing of the virus was revealed. Today the number of confirmed cases is scary, i.e. 9,472,473 in the whole world and 484,236 deaths have been recorded by WHO till 26 June 2020. WHO's global risk assessment is very high [1]. The report is enlightening the lessons learned by India from the highly affected countries.
Keywords: Death rate, different scenario, fight against COVID-19, remedial action, WHO, risk assessment.
Current Signal Transduction Therapy
Title:How India Fights with COVID-19 Learning from Highly Affected Countries
Volume: 16 Issue: 3
Author(s): Pooja Sharma and Karan Veer*
Affiliation:
- Department of Instrumentation & Control Engineering, Dr. B.R. Ambedkar National Institute of Technology, Jalandhar 144011,India
Keywords: Death rate, different scenario, fight against COVID-19, remedial action, WHO, risk assessment.
Abstract: It was 11 March 2020 when the World Health Organization (WHO) declared the name COVID-19 for coronavirus disease and also described it as a pandemic. Till that day 118,000 cases were confirmed of pneumonia with breathing problem throughout the world. At the start of New Year when COVID-19 came into knowledge a few days later, the gene sequencing of the virus was revealed. Today the number of confirmed cases is scary, i.e. 9,472,473 in the whole world and 484,236 deaths have been recorded by WHO till 26 June 2020. WHO's global risk assessment is very high [1]. The report is enlightening the lessons learned by India from the highly affected countries.
Export Options
About this article
Cite this article as:
Sharma Pooja and Veer Karan *, How India Fights with COVID-19 Learning from Highly Affected Countries, Current Signal Transduction Therapy 2021; 16 (3) . https://dx.doi.org/10.2174/1574362415999200807154418
DOI https://dx.doi.org/10.2174/1574362415999200807154418 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design A Further Step Toward an Optimal Ensemble of Classifiers for Peptide Classification, a Case Study: HIV Protease
Protein & Peptide Letters Nanotechnology Advancements in the Diagnosis and Prevention of COVID-19: Past and Future
Coronaviruses COVID-19 Effect: Time to Change the Way of Research
Coronaviruses Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design Challenges of Covid-19 on Adolescent Psychiatric Service Provision in an Independent Inpatient and Outpatient Setting
Adolescent Psychiatry Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review
Current Pharmaceutical Biotechnology New Approaches for the Treatment of Chagas Disease
Current Drug Targets Drug Targets for Rational Design against Emerging Coronaviruses
Infectious Disorders - Drug Targets Combination Therapy with Favipiravir for Treatment of Hospitalized COVID-19 Adults
New Emirates Medical Journal Molecular Dynamics and Inhibition of MERS CoV Papain-like Protease by Small Molecule Imidazole and Aminopurine Derivatives
Letters in Drug Design & Discovery Editorial: From Perfume Oils to Discovering and Making New Molecules: An International Chemical Biology Journey
Combinatorial Chemistry & High Throughput Screening ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Prediction of Michaelis-Menten Constant of Beta-Glucosidases Using Nitrophenyl-beta-D-Glucopyranoside as Substrate
Protein & Peptide Letters The Identification, Characterization and Optimization of Small Molecule Probes of Cysteine Proteases: Experiences of the Penn Center for Molecular Discovery with Cathepsin B and Cathepsin L
Current Topics in Medicinal Chemistry Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I)
Current Pharmaceutical Design Renal Involvement in Pediatric Patients with COVID-19: An Up-to-date Review
Current Pediatric Reviews Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy
Coronaviruses Study of the Relationships between COVID-19, Associated Diseases, and Vitamins
Coronaviruses